Congress planning today: Pain points and opportunities

Less than 1 min read

Between December 2023 and February 2024, we conducted a two-phase multi-methodology research study, collecting feedback from global pharmaceutical company employees whose job roles involve the planning and delivery of congress.

In this report, we uncover the challenges faced by congress planners working in pharma, what is required to mitigate these challenges, and ultimately, how you can improve the execution of future congress events. We explore key research and findings, such as:

‘Congress is still a high-value activity for pharma’
‘Value is being lost in the complexities of delivery’
‘Smarter ROI measurements reveal known unknowns’
‘Overcoming complexities in congress execution’

Download the report.

Insights

Other similar insights

See all insights

The phase II inflection point: Investing to maximize asset value

Harness the collective expertise of our biotech experts to maximize the value of your asset across every step of your journey to commercialization.

The battle against bias in oncology: A call to action at ESMO

A crucial topic gaining momentum is the urgent need to mitigate bias to improve patient outcomes…

Overcoming challenges: Pharma congress execution

Many pharma employees reported that if these challenges are addressed, a congress is far more likely to be successful.